Research programme: bacterial vaccines - ImmunoBiology

Drug Profile

Research programme: bacterial vaccines - ImmunoBiology

Alternative Names: MenBioVax™; T-BioVax™

Latest Information Update: 04 Sep 2013

Price : $50

At a glance

  • Originator ImmunoBiology
  • Class Bacterial vaccines; Heat shock proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Clostridium infections; Helicobacter infections; Meningococcal infections; Tuberculosis

Most Recent Events

  • 29 Aug 2013 Aeras receives 5-year grant from Department for International Development in the United Kingdom for vaccine development in tuberculosis
  • 12 Mar 2013 Preclinical development is ongoing in United Kingdom
  • 17 Oct 2011 Preclinical trials in Helicobacter infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top